Esperion Therapeutics, Inc. (ESPR)
Stock Price:
$38.00 USD
-0.57 (-1.48%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $39.18 +1.18 (3.11%) Aug 7, 7:31 PM
Key Info
| Market Cap |
1.05B |
| Revenue (ttm) |
4.79M |
| Net Income (ttm) |
-262.79M |
| Shares Out |
27.62M |
| EPS (ttm) |
-9.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$38.00 |
| Previous Close |
$38.57 |
| Change ($) |
-0.57 |
| Change (%) |
-1.48% |
| Day's Open |
38.49 |
| Day's Range |
37.94 - 39.11 |
| Day's Volume |
645,608 |
| 52-Week Range |
24.82 - 76.98 |
More Stats
| Market Cap |
1.05B |
| Enterprise Value |
1.06B |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.62M |
| Float |
25.10M |
| EPS (basic) |
-9.66 |
| EPS (diluted) |
-9.64 |
| FCF / Share |
-8.44 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.13M |
| Short Ratio |
16.98 |
| Short % of Float |
44.21% |
| Beta |
1.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
219.32 |
| PB Ratio |
60.92 |
| Revenue |
4.79M |
| Operating Income |
-254.48M |
| Net Income |
-262.79M |
| Free Cash Flow |
-232.33M |
| Net Cash |
-9.10M |
| Net Cash / Share |
-0.33 |
| Gross Margin |
-569.43% |
| Operating Margin |
-5,318.20% |
| Profit Margin |
-5,492.00% |
| FCF Margin |
-4,855.46% |
| ROA |
-76.44% |
| ROE |
-421.26% |
| ROIC |
-219.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
9 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$87.73*
(130.87% upside)
Low
42.0
Current: $38.00
High
191.0
Target: 87.73
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 148 | - | - | - | - | - | - | - | - |
| Gross Profit | 148 | - | - | - | - | - | - | - | - |
| Operating Income | -93.10 | -205 | -169 | -76.15 | -50.04 | -36.22 | -22.76 | -10.20 | -10.16 |
| Net Income | -97.17 | -202 | -167 | -74.98 | -49.78 | -36.38 | -26.09 | -11.74 | -10.82 |
| Shares Outstanding | 27.09 | 26.75 | 23.93 | 22.54 | 22.02 | 16.37 | 7.89 | 0.32 | 0.30 |
| Earnings Per Share | -3.59 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -3.31 | -36.31 | -36.22 |
| Operating Cash Flow | -70.34 | -149 | -131 | -47.73 | -38.16 | -32.02 | -18.11 | -10.81 | -9.07 |
| Capital Expenditures | -0.95 | -0.15 | -0.02 | -0.09 | -0.30 | -0.86 | 0.17 | - | 0.01 |
| Free Cash Flow | -71.29 | -149 | -131 | -47.82 | -38.46 | -32.88 | -17.94 | -10.81 | -9.06 |
| Cash & Equivalents | 202 | 136 | 200 | 212 | 212 | 106 | 60.06 | 6.51 | 1.57 |
| Total Debt | 134 | - | 1.05 | 2.73 | 4.29 | 4.87 | - | 22.77 | 6.90 |
| Net Cash / Debt | 67.60 | 136 | 199 | 209 | 208 | 101 | 60.06 | -16.26 | -5.33 |
| Assets | 214 | 143 | 278 | 245 | 296 | 143 | 78.29 | 7.31 | 2.18 |
| Liabilities | 194 | 64.33 | 33.14 | 16.61 | 8.31 | 9.72 | 4.20 | 24.70 | 8.24 |
| Book Value | 19.95 | 79.12 | 245 | 229 | 287 | 134 | 74.09 | -41.36 | -30.03 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Esperion Therapeutics, Inc. |
| Country |
United States |
| Employees |
193 |
| CEO |
Tim M. Mayleben |
Stock Information
| Ticker Symbol |
ESPR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ESPR |
| IPO Date |
June 26, 2013 |
Description
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.